Vasodilator effects of cromakalim and HA 1077 in diabetic rat aorta

Swiss Medical Weekly

Volumn 142, Issue APRIL, 2012, Pages

  Gurpinar, Tugba ^a   Gok, Sule ^a  

^a CELAL BAYAR UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Aorta; Cromakalim; Fasudil; Rho kinase

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CROMAKALIM; FASUDIL; N(G) NITROARGININE METHYL ESTER; RHO KINASE; STREPTOZOCIN; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; DRUG DERIVATIVE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY ENDOTHELIUM; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; VASODILATATION; WISTAR RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; ENZYMOLOGY; IN VITRO STUDY; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; AORTA; CROMAKALIM; DIABETES MELLITUS; KATP CHANNELS; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; STREPTOZOCIN; VASODILATION; VASODILATOR AGENTS;

EID: 84860771283     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13558     Document Type: Article

References (32)

1. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005;109:143-59. (Pubitemid 41117297)
2. Lockhart CJ, Hamilton PK, McVeigh KA, McVeigh GE. A cardiologist view of vascular disease in diabetes. Diabetes Obes Metab. 2008;10:279-92. (Pubitemid 351386025)
3. Xavier FE, Davel AP, Rossoni LV, Vassallo DV. Time-dependent hyperreactivity to phenylephrine in aorta from untreated diabetic rats: role of prostanoids and calcium mobilization. Vascul Pharmacol. 2003;40:67-76. (Pubitemid 36401581)
4. Brayden JE. Functional roles of KATP channels in vascular smooth muscle. Clin Exp Pharmacol Physiol. 2002;29:312-6. (Pubitemid 34227066)
5. Standen NB, Quayle JM. K+ channel modulation in arterial smooth muscle. Acta Physiol Scand. 1998;64:549-57. (Pubitemid 29015673)
6. Strutyns'kyǐ RB, Moǐbenko OO, Pyvovar SM, Dosenko VI, Iahupol's'kyǐ LM. ATP-sensitive potassium channels and changes in their functional activity during streptozocin induced diabetes mellitus. Fiziol Zh. 2003;49:22-30.
7. Zimmermann PA, Knot HJ, Stevenson AS, Nelson MT. Increased myogenic tone and diminished responsiveness to ATP-sensitive K+ channel openers in cerebral arteries from diabetic rats. Circ Res. 1997;81:996-1004. (Pubitemid 27514949)
8. Mayhan WG, Faraci FM. Responses of cerebral arterioles in diabetic rats to activation of ATP-sensitive potassium channels. Am J Physiol. 1993;265:152-7.
9. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325-58. (Pubitemid 37222274)
10. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res. 2000;261:44-5.
11. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-4. (Pubitemid 27485693)
12. Shimokawa H. Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 2007;28:296-302. (Pubitemid 46818464)
13. Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol. 2011;7:657-71.
14. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2011;301:287-96.
15. Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N, et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol. 2007;192:595-603. (Pubitemid 46455962)
16. Murat N, Soner BC, Demir O, Esen A, Gidener S. Contractility of diabetic human corpus cavernosum smooth muscle in response to serotonin mediated via Rho-kinase. Pharmacology. 2009;84:24-8.
17. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia- induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation. 2005;111:3261-8. (Pubitemid 40874999)
18. Yao L, Romero MJ, Toque HA, Yang G, Caldwell RB, Caldwell RW. The role of RhoA/Rho kinase pathway in endothelial dysfunction. J Cardiovasc Dis Res. 2010;1:165-70.
19. Begum N, Sandu OA, Duddy N. Negative regulation of rho signaling by insulin and its impact on actin cytoskeleton organization in vascular smooth muscle cells: role of nitric oxide and cyclic guanosinemono-phosphate signaling pathways. Diabetes. 2002;51:2256-63. (Pubitemid 34729033)
20. Chitaley K, Webb RC. Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signaling. Hypertension. 2002;39:438-42. (Pubitemid 34165162)
21. Negi G, Kumar A, Kaundal RK, Gulati A, Sharma SS. Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology. 2010;58:585-92.
22. McCulloch AI, Randall MD. Modulation of vasorelaxant responses to potassium channel openers by basal nitric oxide in the rat isolated superior mesenteric arterial bed. Br J Pharmacol. 1996;117:859-66. (Pubitemid 26075964)
23. Deka DK, Raviprakash V, Mishra SK. Basal nitric oxide release differentially modulates vasodilations by pinacidil and levcromakalim in goat coronary artery. Eur J Pharmacol. 1998;348:11-23. (Pubitemid 28266748)
24. Deka DK, Mishra SK, Raviprakash V. L-arginine-induced dilatation of goat coronary artery involves activation of K (ATP) channels. Eur J Pharmacol. 2009;609:113-7.
25. Kinoshita H, Iwahashi S, Kakutani T, Mizumoto K, Iranami H, Hatano Y. The role of endothelium-derived nitric oxide in relaxations to levcromacalim in the rat aorta. Jpn J Pharm. 1999;81:362-6. (Pubitemid 30076664)
26. Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation. 2005;111:2741-7. (Pubitemid 40791544)
27. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91:391-2. (Pubitemid 40299237)
28. Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2007;568:242-7. (Pubitemid 46976901)
29. MA Creager, TF Lüscher, F Cosentino, JA Beckman. Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003;108:1527-32. (Pubitemid 37176462)
30. Shen JZ, Zheng XF. Characteristics of impaired endothelium-dependent relaxation of rat aorta after streptozotocin-induced diabetes. Zhongguo. Yao Li Xue Bao. 1999;20:844-50.
31. Potenza MA, Gagliardi S, Nacci C, Carratu' MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem. 2009;16:94-112.
32. Löhn M, Steioff K, Bleich M, Busch AE, Ivashchenko Y. Inhibition of Rho-kinase stimulates nitric oxide-independent vasorelaxation. Eur J Pharmacol. 2005;179-86. (Pubitemid 40126854)